Business
27 May, 2026
Morepen Laboratories Q4 net profit falls 22.7 pc to Rs 15.70 cr
Business To Business, New Delhi, 27th May, 2026: Morepen Laboratories on Tuesday reported a 22.7 per cent decline in net profit for the March quarter of FY26.
According to the company’s regulatory filing:
- Net profit for the January–March 2026 quarter stood at ₹15.70 crore
- Net profit in the corresponding quarter a year earlier was ₹20.31 crore
Despite the decline in profitability, the company recorded modest revenue growth:
- Revenue in Q4 FY26: ₹484.71 crore
- Revenue in Q4 FY25: ₹465.85 crore
- Year-on-year growth: 4.04 per cent
Morepen Laboratories operates in pharmaceuticals, active pharmaceutical ingredients (APIs), diagnostics, and consumer healthcare products.
The results indicate that while revenues improved slightly, profitability was impacted during the quarter, potentially due to factors such as:
- Higher operational costs
- Margin pressures
- Input cost fluctuations
- Competitive market conditions
The company continues to maintain a presence in both domestic and international healthcare markets.